# LH-RH ANALOGS IN BREAST AND OVARIAN CANCER

> **NIH NIH R01** · TULANE UNIVERSITY OF LOUISIANA · 1991 · $169,204

## Abstract

Analogs of luteinizing hormone-releasing hormone (LH-RH) given
alone and in combination will be tested in animal models of
hormone-dependent mammary carcinoma and in nude mice and nude rats
bearing transplanted MCF-7, Beta T-20 and other human breast cancer
cell lines, human ovarian tumors (e.g. OVCAR-3 line) and
endometrial adenocarcinoma.  Our studies will include the
investigation of mammary tumor growth inhibition induced by:  1)
controlled delivery systems based on the microcapsules or
microparticles of the agonist D-Trp-6-LH-RH in poly(D,L-lactide-
co-glycolide) (pLGA) for once-a-month administration; 2)
combination regimens of D-Trp-6-LH-RH microcapsules with a) other
peptides, especially superactive somatostatin analogs of D-Phe-Cys-
Tyr-D-Trp-Lys-Val-Cys-Trp-Nh2 (RC-160) class and microcapsules
thereof; b) with antiestrogens such as Tamoxifen; c)
chemotherapeutic agents such as Ifosfamide, Mitomycin C and
Cisplatinum; 3) controlled delivery systems based on the
microcapsule (pLGA) or implant formulations of new LH-RH
antagonists of X-R1-R2-D-Trp-Ser-Tyr-R6-Leu-Arg-Pro-R10-NH2 class;
4) combinations of LH-RH antagonists with somatostatin analogs,
antiestrogens, and chemotherapeutic agents; 5) continued synthesis
of various LH-RH analogs containing cytostatic radicals such as
Melphalan, Aziridine, Mitomycin C and their evaluation in models
of breast and ovarian cancer as targeted hormonal carriers for
chemotherapeutic agents; 6) in vitro evaluation of direct effects
of LH-RH analogs, somatostatin analogs and cytostatic effect of
peptides with antineoplastic radicals on human breast cancer lines;
7) measurements of membrane receptors for LH-RH, somatostatin,
prolactin and growth factors such as EGF and IGF-1 in tumor tissue
in the course of the treatment as well as blood and tissue levels
of EGF and IGF-1; 8) the microcapsules of D-Trp-6-LH-RH and of an
LH-RH antagonist given alone or in combination with chemotherapy
will be also investigated in various models of ovarian and uterine
tumors; 9) detailed histological evaluations will be performed to
correlate morphological changes with tumor regression.  The aim of
this project will be to improve the response to LH-RH agonists in
mammary cancer by combined therapy with other agents, especially
somatostatin analogs, evaluate the usefulness of the LH-RH
antagonists and analogs with cytostatic radicals for the inhibition
of this tumor, and investigate the possible application of LH-RH
agonists and antagonists for the treatment of ovarian cancer and
neoplasms of the female genital tract.

## Key facts

- **NIH application ID:** 3179442
- **Project number:** 5R01CA040004-06
- **Recipient organization:** TULANE UNIVERSITY OF LOUISIANA
- **SAM.gov UEI:** XNY5ULPU8EN6
- **Principal Investigator:** ANDREW V SCHALLY
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1991
- **Award amount:** $169,204
- **Award type:** 5
- **Project period:** 1985-09-01 → 1992-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3179442

## Citation

> US National Institutes of Health, RePORTER application 3179442, LH-RH ANALOGS IN BREAST AND OVARIAN CANCER (5R01CA040004-06). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3179442. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*